Last reviewed · How we verify
CapeOX（Capecitabine+Oxaliplatin）
CapeOX（Capecitabine+Oxaliplatin） is a Combination chemotherapy regimen Small molecule drug developed by Peking University Cancer Hospital & Institute. It is currently in Phase 3 development for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer, Gastric cancer.
CapeOX combines capecitabine, a fluoropyrimidine prodrug that inhibits thymidylate synthase, with oxaliplatin, a platinum agent that forms DNA crosslinks, to provide synergistic cytotoxic activity against cancer cells.
CapeOX combines capecitabine, a fluoropyrimidine prodrug that inhibits thymidylate synthase, with oxaliplatin, a platinum agent that forms DNA crosslinks, to provide synergistic cytotoxic activity against cancer cells. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer, Gastric cancer.
At a glance
| Generic name | CapeOX（Capecitabine+Oxaliplatin） |
|---|---|
| Sponsor | Peking University Cancer Hospital & Institute |
| Drug class | Combination chemotherapy regimen |
| Target | Thymidylate synthase (capecitabine); DNA (oxaliplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Capecitabine is converted to 5-fluorouracil in tumor tissue, disrupting nucleotide synthesis and DNA/RNA function. Oxaliplatin forms platinum-DNA adducts that prevent DNA replication and transcription. Together, these agents provide complementary mechanisms of action with enhanced efficacy in colorectal and other solid tumors.
Approved indications
- Metastatic colorectal cancer
- Adjuvant treatment of stage III colorectal cancer
- Gastric cancer
- Pancreatic cancer
Common side effects
- Hand-foot skin reaction
- Nausea and vomiting
- Diarrhea
- Neutropenia
- Peripheral neuropathy
- Fatigue
- Anemia
Key clinical trials
- A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer (PHASE2)
- SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases (PHASE2)
- Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma (PHASE2)
- A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer (PHASE1)
- Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer (PHASE2)
- Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer (PHASE2)
- Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CapeOX（Capecitabine+Oxaliplatin） CI brief — competitive landscape report
- CapeOX（Capecitabine+Oxaliplatin） updates RSS · CI watch RSS
- Peking University Cancer Hospital & Institute portfolio CI
Frequently asked questions about CapeOX（Capecitabine+Oxaliplatin）
What is CapeOX（Capecitabine+Oxaliplatin）?
How does CapeOX（Capecitabine+Oxaliplatin） work?
What is CapeOX（Capecitabine+Oxaliplatin） used for?
Who makes CapeOX（Capecitabine+Oxaliplatin）?
What drug class is CapeOX（Capecitabine+Oxaliplatin） in?
What development phase is CapeOX（Capecitabine+Oxaliplatin） in?
What are the side effects of CapeOX（Capecitabine+Oxaliplatin）?
What does CapeOX（Capecitabine+Oxaliplatin） target?
Related
- Drug class: All Combination chemotherapy regimen drugs
- Target: All drugs targeting Thymidylate synthase (capecitabine); DNA (oxaliplatin)
- Manufacturer: Peking University Cancer Hospital & Institute — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic colorectal cancer
- Indication: Drugs for Adjuvant treatment of stage III colorectal cancer
- Indication: Drugs for Gastric cancer
- Compare: CapeOX（Capecitabine+Oxaliplatin） vs similar drugs
- Pricing: CapeOX（Capecitabine+Oxaliplatin） cost, discount & access